Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.265 +0.075 (+6.30%)
Streaming Delayed Price Updated: 3:50 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Soared Today
Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know. 
Via The Motley Fool
What's Going On With Coherus BioSciences Stock?
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for 
Via Benzinga
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Analyst Expectations for Coherus BioSciences's Future
 
Via Benzinga
4 Analysts Have This to Say About Coherus BioSciences
 
Via Benzinga
Why Coherus BioSciences Stock Popped Today
The immuno-oncology leader delivered a strong second quarter. 
Via The Motley Fool
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! 
Via InvestorPlace
Analyst Ratings for Coherus BioSciences
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Popped Today
Coherus resubmitted a license application for a key product today. Here's what investors need to know. 
Via The Motley Fool
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
From Coherus BioSciences, Inc.
Via GlobeNewswire
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of... 
Via Benzinga
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Completes Surface Oncology Acquisition
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Was Plunging This Week
The "index effect" is real, although typically not long-lasting. 
Via The Motley Fool
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
ABNB and BX will join Sept. 18 as part of a quarterly rebalancing. 
Via Investor's Business Daily
Topics Stocks
Coherus BioSciences to Participate at Upcoming September Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting 
From Surface Oncology, Inc.
Via GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback